Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent, issued on July 28, 2026, protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The Canadian patent expands Greenland Mines’ intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. This broadening of patent protection strengthens the company’s position in the competitive gene therapy landscape, potentially impacting the development of treatments for debilitating neurological conditions that affect millions worldwide.
Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The progression of these candidates toward regulatory engagement suggests that the company is moving closer to clinical trials, which could bring novel therapies to patients suffering from neurodegenerative diseases.
The company’s biotech division focuses on Klotho’s KLTO‑202 primary indication for ALS, a devastating motor neuron disease with limited treatment options. The advancement of KLTO-202 into GMP manufacturing represents a critical step in the development pipeline, potentially accelerating the timeline for human studies. For the industry, the securing of intellectual property rights in Canada—a key market for pharmaceutical innovation—may encourage further investment in Klotho-based approaches and gene therapy platforms.
Greenland Mines is a Nasdaq-listed company with two operating divisions: mining and biotech. Its mining division is focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML. For full terms of use and disclaimers, visit http://IBN.fm/Disclaimer. This announcement underscores the potential impact of gene therapy advancements on neurological disease treatment, offering hope to patients and signaling progress in the biotech sector.
